{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-026692","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.465732+00:00","generated_at":"2026-06-06T07:09:27.947020+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sana reports SC291 ARDENT interim data with responses and immune evasion; cash $205.4M","bullets":["Preliminary cash, cash equivalents and marketable securities as of Jan 2, 2024: approximately $205.4 million.","ARDENT interim: 4 evaluable patients; 3 partial responses including ongoing complete responses; no DLTs, GVHD, or CRS/ICANS.","HIP-edited CAR T cells evaded innate and adaptive immune responses in all 4 evaluable patients; non-HIP cells were recognized.","IND cleared for GLEAM (lupus/vasculitis) and VIVID (CD22 CAR T) trials; data expected in 2024.","Preclinical: HIP primary islets in diabetic NHP achieved insulin independence for 6 months without immunosuppression; IST of UP421 authorized."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-026692","json":"https://secwatch.observer/filing/0001193125-24-026692.json","markdown":"https://secwatch.observer/filing/0001193125-24-026692.md","text":"https://secwatch.observer/filing/0001193125-24-026692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312524026692/0001193125-24-026692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312524026692/d180813d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:09:27.947020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}